Glenmark inks pact with Hengrui Pharma for cancer therapy Trastuzumab Rezetecan

Glenmark inks pact with Hengrui Pharma for cancer therapy Trastuzumab Rezetecan

Glenmark Pharmaceuticals Ltd on Wednesday announced signing of an exclusive licence and collaboration pact with Hengrui Pharma for development and commercialisation of Trastuzumab Rezetecan that is aimed at treating different types of cancer. The company’s arm Glenmark Specialty SA has entered into an exclusive licence and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811),…

Read More